Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab with concurrent chemoradiotherapy for stage IV hypopharyngeal carcinoma without distant metastasis
ChiCTR2100043981Phase 2Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Jul 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial of toripalimab in hypopharyngeal cancer (2 arms), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoints: Efficacy and Safety. Started Jul 2019; status: recruiting.
02
Drugs
toripalimab
03
Conditions
hypopharyngeal cancer
Beyond the preview
Go deeper on ChiCTR2100043981.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100043981.